Peter Villax
Chairman @ Bionova Capital
Peter Villax is a seed investor at Bionova Capital focused on Medical and Hospital. Peter Villax is Bionova Capital’s Chairman. He joined Hovione in 1982 as a computer programmer and led Hovione’s computerization, then switched to pharmaceutical development in 1990 and soon became interested in in pulmonary delivery. His disposable dry-powder inhaler TwinCaps, licensed to Daiichi Sankyo for the delivery of Influenza drug Inavir®,continues to be the only commercial device of its kind in the world, and has helped Daiichi Sankyo become the market leader in influenza products in Japan. He acquired significant experience as an inventor of devices, as a patentholder and as licensor of technology patents. In 2013 together with Miguel Calado, he was involved in a 7-figure royalty monetization deal with a US-based financial company, under which Hovione sold the future income streams earned under a license agreement. Peter Villax is also active in civic duties, as president of the Family Business Association in Portugal, a member of three University faculty boards (Pharmacy in U. Coimbra, Medicine in U.Lisbon and the Institute of Chemical and Biological Technology in U.Nova) as well as of other organizations. He is a lecturer and a frequent speaker at scientific, academic and business conferences and an ocasional participant in TV programmes.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Peter Villax invests in
Stages Peter Villax invests in
Countries Peter Villax invests in
Investment Focus
Industry
- Medical 1 (50%)
- Hospital 1 (50%)
- Health Care 1 (50%)
- Pharmaceutical 1 (50%)
Country
- Spain 1 (50%)
- Portugal 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Delox
|
Delox is a spin-off of the Faculty of Sciences of the University of Lisbon (FCUL), whose goals consist in the design, development, and production of a vast portfolio of automatic biodecontamination robots. Target applications include the sterilization of medical devices in hospitals, health centers and field hospitals (for humanitarian missions,catastrophe situations, and war zones); room biodecontamination in hospitals, pharma, food industry and space; and laboratory equipment biodecontamination. | $785.5K / Seed / May 18, 2022 | |
Vaxdyn
|
Vaxdyn develops vaccines using novel technology. They offers pathogen vaccines for preventing antibiotics-resistant infections. Their customers' inquiries are addressed through phone, email, and online applications. | $355.5K / Seed / Mar 08, 2021 |
Co-Investors
Arquimea Ingeniera
1 deal together
Caixa Capital
1 deal together
Fundacion Botin
1 deal together
Kiilto Ventures
1 deal together
Reig Jofre
1 deal together
About Bionova Capital
Bionova Capital, previously known as Hovione Capital, is a healthcare-focused venture capital firm, investing in early-stage life science companies. It was founded in 2015 by the shareholders of Hovione, one of the largest pharmaceutical companies in Portugal, with manufacturing and research operations in USA, Ireland, China and Portugal. BionovaCapital invests in groundbreaking therapeutics, medtech and digital health startups across Europe.
Bionova Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
João Ventura Fernandes
Venture Partner
|
|||
|
Peter Villax
Chairman
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Peter Villax invest in?
Peter Villax invests primarily in Medical, Hospital and Health Care startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Peter Villax last invest?
The most recent investment recorded for Peter Villax closed in May 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
